Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate

Author(s):  Wu George, Yeung Stanley, Chen Frank

Issue:  Jan/Feb 2017 - Volume 21, Number 1
View All Articles in Issue

Page(s):  66-75

Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 1
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 2
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 3
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 4
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 5
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 6
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 7
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 8
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 9
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 10

Download in electronic PDF format for $75

Abstract:  Neurokinin-1 receptor antagonist, 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone combination therapy is the standard of care for the prevention of chemotherapy-induced nausea and vomiting. Herein, we describe the physical and chemical stability of an injectable emulsion of the Neurokinin-1 receptor antagonist rolapitant 185 mg in 92.5 mL (free base, 166.5 mg in 92.5 mL) admixed with either 2.5 mL of dexamethasone sodium phosphate (10 mg) or 5 mL of dexamethasone sodium phosphate (20 mg). Admixtures were prepared and stored in two types of container closures (glass and Crystal Zenith plastic bottles) and four types of intravenous administration tubing sets (or intravenous tubing sets). The assessment of the physical and chemical stability was conducted on admixtures packaged in bottled samples stored at room temperature (20°C to 25°C under fluorescent light) and evaluated at 0, 1, and 6 hours. For admixtures in intravenous tubing sets, the assessment of physicochemical stability was performed after 0 and 7 hours of storage at 20°C to 25°C, and then after 20 hours (total 27 hours) under refrigeration (2°C to 8°C) and protected from light. Physical stability was assessed by visually examining the bottle contents under normal room light and measuring turbidity and particulate matter. Chemical stability was assessed by measuring the pH of the admixture and determining drug concentrations through high-performance liquid chromatographic analysis. Results showed that all samples were physically compatible throughout the duration of the study. The admixtures stayed within narrow and acceptable ranges in pH, turbidity, and particulate matter. Admixtures of rolapitant and dexamethasone were chemically stable when stored in glass and Crystal Zenith bottles for at least 6 hours at room temperature, as well as in the four selected intravenous tubing sets for 7 hours at 20°C to 25°C and then for 20 (total 27 hours) hours at 2°C to 8°C. No loss of potency of any admixed component occurred in the samples stored at the temperature ranges studied.

Related Keywords: George Wu, PhD, Stanley Yeung, PharmD, Frank Chen, PhD, rolapitant, neurokinin-1 receptor antagonist, NK-1 inhibitor, 5-hydroxytryptamine-3 receptor antagonist, dexamethasone, 5-HT3 inhibitor, serotonin pathway, substance P/NK-1 pathway, drug combination, drug admixtures, chemotherapy-induced nausea and vomiting, emesis, storage containers, intravenous tubing sets, antiemetic agents, injectable emulsion compound, stability, compatibility

Related Categories: CANCER AND AIDS, GASTROENTEROLOGY, PARENTERALS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, STORAGE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate
Wu George
, Yeung Stanley, Chen Frank
Jan/Feb 2017
Pg. 66-75

Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride
Wu George
, Yeung Stanley, Chen Frank
Jan/Feb 2017
Pg. 76-82

Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride
Wu George
, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly
Jan/Feb 2018
Pg. 86-94

Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection
Wu George
, Powers Dan, Yeung Stanley, Chen Frank
Jan/Feb 2018
Pg. 76-85

Rolapitant Injectable Emulsion with Dexamethasone Sodium Phosphate Admixture
Allen Loyd V Jr
May/Jun 2018
Pg. 237

Rolapitant Injectable Emulsion with Palonosetron Hydrochloride Admixture
Allen Loyd V Jr
Mar/Apr 2018
Pg. 151

The Basics of Compounding Emulsions, Part 2
Allen Loyd V Jr
May/Jun 2001
Pg. 198-201

Compatibility and Stability of Aloxi (Palonosetron Hydrochloride) Admixed With Dexamethasone Sodium Phosphate
Trissel Lawrence A
, Zhang Yanping
Sep/Oct 2004
Pg. 398-403

Dexamethasone Sodium Phosphate Ophthalmic Solution: Equivalent to 0.1% Dexamethasone Phosphate
Allen Loyd V Jr
Nov/Dec 2015
Pg. 508

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2014
Pg. 278-286

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Mar/Apr 2024
Pg. 100-109

Stability of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone Sodium Phosphate in 0.9% Sodium Chloride Stored in Polypropylene Syringes
Anderson Collin R
, Halford Zachery, MacKay Mark
Jul/Aug 2015
Pg. 344-347

Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel
, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2007
Pg. 520-524

Dextromethorphan, an NMDA receptor antagonist, as a Treatment for Pain
Mishkan Emilyn S
Sep/Oct 2005
Pg. 339-346

Book Review: The NMDA Receptor
Jones Marty
Jan/Feb 2000
Pg. 26-27

Compatibility and Stability of Linezolid Injection Admixed with Gentamicin Sulfate and Tobramycin Sulfate
Xu Quanyun A
, Trissel Lawrence A, Zhang Yanping, Williams Kimberly Y
Nov/Dec 2000
Pg. 476-479

Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini HC
, Loures S, Lima LC, Ferreira AO, Brandão MA
Mar/Apr 2016
Pg. 167-174

Quantification of Total Dexamethasone Phosphate Delivery by Iontophoresis
Anderson Carter R
, Boeh Stephen D, Morris Russell L, Sembrowich Walter L, Panus Peter C
Mar/Apr 2003
Pg. 155-159

Compounding for the Treatment of COVID-19 and Long COVID, Part 3: The Role of Toll-like Receptors in SARS-CoV-2 Infection and COVID Development
Riepl Mike
, Kaiser Joe
May/Jun 2023
Pg. 192-200

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Return to Top